60 results
Page 3 of 3
6-K
EX-99.1
3t26n
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
EX-99.1
nwxfb21zn
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
424B2
5fj7ozyc
24 Jan 20
Prospectus for primary offering
7:24am
6-K
7lw6 snj76o
21 Jan 20
Current report (foreign)
5:31pm
424B5
vua9ia7fvl mgwy5
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
2ryop60k
27 Dec 19
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
7:51am
20-F/A
EX-10.15
u2x5vv c897
23 Aug 19
Annual report (foreign) (amended)
5:00pm
6-K
EX-99.1
ai0iz157
2 Jul 19
Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
7:32am
20-F/A
EX-10.15
kie4fi7fcp
26 Jun 19
Annual report (foreign) (amended)
6:07am
6-K
EX-99.1
8qn 2a9px
7 Mar 19
Zai Lab Announces Financial Results and Corporate Update for Full Year 2018
7:36am
424B4
lglidh zrnz
7 Sep 18
Prospectus supplement with pricing info
12:00am
6-K
EX-99.1
49jw8cvo9xay
14 Aug 18
Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors
7:36am
20-F
ya8sr2bni5c2qf ka
30 Apr 18
Annual report (foreign)
9:07am
6-K
EX-99.1
ujuxxeway 3e8c
25 Apr 18
Global Strategic Development Collaboration for ETX2514
12:00am